Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

Ottonagy Jan. 31 at 2:57 AM

$CATX If this shit goes back to $6 I will sell it for good not going to make this mistake. This shit can go bankrupt, delisted or go back up to f…ing $6+ just don’t go sideways for like another year for f.u.c.k’s sake!

0 · Reply

Ottonagy Jan. 31 at 2:53 AM

$CATX I should have sold this at $6 now I’m probably going to be stuck in this because I’m not going to sell it under $6 f this s.h.i.t. Man it makes me so angry 😠 I can’t sleep 😂

1 · Reply

drdenturedds Jan. 31 at 12:12 AM

$CATX I just checked fintel.io in order to find out what happened today with the short interest and what I found out just doesn't make sense to me given the previous short interest of 33 million shares to a little over 2 million shares in one day. Given today's volume this just doesn't appear to make much sense to me. Thoughts?

1 · Reply

JDinvestments Jan. 30 at 10:19 PM

$CATX Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. Would be crazy if Sanofi made a move on Catx STRONG BUYOUT 🔥🔥🔥💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

UgoGreg Jan. 30 at 10:04 PM

$CATX https://youtu.be/Oc7ZPBJYyrE

0 · Reply

Ottonagy Jan. 30 at 9:55 PM

$CATX AI prediction for next week 🤔

0 · Reply

jto2 Jan. 30 at 9:44 PM

If a tender offer were ever to come into play, spot price would just be noise. $3.79 or $1.00 wouldn’t change what a potential acquirer would be willing to pay. I’m holding for a potential tender offer, and I don’t think the wait will be long — especially with Sanofi’s exit effectively creating $CATX in what looks like a monopoly setup, and yesterday’s 80M volume looking more like institutional positioning than retail noise. Enjoy the weekend, longs.

0 · Reply

jerseymike3 Jan. 30 at 9:26 PM

@drdenturedds what do you think happened to $CATX today?

1 · Reply

Filbert3 Jan. 30 at 9:20 PM

$CATX bear dancing today. Have a nice weekend my old long friends.

0 · Reply

IdiotSavant1 Jan. 30 at 9:03 PM

$CATX All that matters is whether you believe that this company will develop a proven means of identifying cancer cells and successfully destroying them. So far all of their trials are moving in that direction with positive results. So if you believe that is the case then it only matters where the price gets to once they reach that ultimate goal. Institutions seem to realize that, Lantheus seems to realize that, the FDA seems to realize that and the list goes on. If the shorters, flippers, pumpers and dumpers happen to make some coin along the way then so be it and hooray for them. I don't begrudge anyone that makes an honest buck. However, I'm a big picture person and have done enough research to realize that this company, and the people behind it, have a chance to really succeed, despite the nay sayers and name callers on this board.

1 · Reply

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Jan 14, 2026, 9:46 PM EST - 16 days ago

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 9, 2026, 7:00 AM EST - 21 days ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2025, 7:00 AM EST - 6 weeks ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 7:00 AM EST - 2 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 11, 2025, 11:11 PM EST - 2 months ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:05 PM EST - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 24, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 20, 2025, 5:05 PM EDT - 3 months ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 4:00 AM EDT - 3 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Sep 3, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Aug 26, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 13, 2025, 6:45 AM EDT - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 2, 2025, 8:53 AM EDT - 6 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 6 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 7 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 7 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 8 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 10 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 11 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 11 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Ottonagy Jan. 31 at 2:57 AM

0 · Reply

Ottonagy Jan. 31 at 2:53 AM

$CATX I should have sold this at $6 now I’m probably going to be stuck in this because I’m not going to sell it under $6 f this s.h.i.t. Man it makes me so angry 😠 I can’t sleep 😂

1 · Reply

drdenturedds Jan. 31 at 12:12 AM

1 · Reply

JDinvestments Jan. 30 at 10:19 PM

0 · Reply

UgoGreg Jan. 30 at 10:04 PM

$CATX https://youtu.be/Oc7ZPBJYyrE

0 · Reply

Ottonagy Jan. 30 at 9:55 PM

$CATX AI prediction for next week 🤔

0 · Reply

jto2 Jan. 30 at 9:44 PM

0 · Reply

jerseymike3 Jan. 30 at 9:26 PM

@drdenturedds what do you think happened to $CATX today?

1 · Reply

Filbert3 Jan. 30 at 9:20 PM

$CATX bear dancing today. Have a nice weekend my old long friends.

0 · Reply

IdiotSavant1 Jan. 30 at 9:03 PM

1 · Reply

JDinvestments Jan. 30 at 8:50 PM

$CATX Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space Seeking alpha article 🔥🔥🔥💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

RadioIsotope25 Jan. 30 at 8:48 PM

$CATX

0 · Reply

Miura1957 Jan. 30 at 8:47 PM

$CATX but at least it’s not 2.50…yet…

0 · Reply

Miura1957 Jan. 30 at 8:46 PM

$CATX that was not the follow up day we were hoping for…

1 · Reply

Hoosiers01 Jan. 30 at 8:23 PM

$CATX - just keep in mind the previous symbol ISR and that’s enough to remind anyone dumb enough to buy and hold this over 30+ years this is going back to $.22 ( 2.20) before it hits $6. in 2027 /2028 if lucky … believe it or not Enron / Bear Stearns/ Lehman Bros. would of been better investments than dealing with the crooks at ISR and present management…..

0 · Reply

JDinvestments Jan. 30 at 7:52 PM

$CATX bash 🤡 was waiting 4 yrs to wake up 🤣🤣🤣 penny less and stupid no doubt 👋👋👋🤡

1 · Reply

raptorsGOAT Jan. 30 at 7:41 PM

$CATX Correct, nothing has changed about this company. Which is why it will go back down to $2.5 rather than up to $6 like it did during the scam pump.

0 · Reply

JDinvestments Jan. 30 at 7:40 PM

$CATX shorts wondering WTF volume gone holding record short positions 🤣🤣🤣 news 🔥🔥🔥 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

1 · Reply

raptorsGOAT Jan. 30 at 7:39 PM

$CATX Translating pumpernese: Some schmuck should come buy these shares off me before it goes to $2.80. Why are you acting as if 6 million is merely a down day in terms of volume when average volume per day for this stock is 2.8 million? You want people to drink the kool aid that this company has already been bought?

0 · Reply

JAXTWIN Jan. 30 at 7:14 PM

$CATX But what I am really talking about ? lol I’m about the gimme dat.

0 · Reply

JAXTWIN Jan. 30 at 7:13 PM

$CATX if it aint $3, it’s not for meeeeeeee!

0 · Reply

Iveyy Jan. 30 at 7:08 PM

$CATX pinch point. GLTA

0 · Reply

Market Cap	316.68M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	7,721,700
Avg Vol	3,109,352
Day's Range	N/A - N/A
Shares Out	74.34M
Stochastic %K	39%
Beta	1.18
Analysts	Strong Sell
Price Target	$12.15